Skip Over Navigation Links
National Institutes of Health
Find more NIMH pages about: Schizophrenia

Science News about Schizophrenia

Find Press Releases and Science Updates by Topic

Violence in Schizophrenia Patients More Likely Among Those with Childhood Conduct Problems
July 2, 2007 • Press Release
Some people with schizophrenia who become violent may do so for reasons unrelated to their current illness, according to a new study analyzing data from the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE).
Antipsychotic Medications for Schizophrenia on Equal Footing in Improving Patients’ Thinking Skills
June 4, 2007 • Science Update
Patients with schizophrenia taking antipsychotic medications experience a small improvement in thinking and reasoning skills (neurocognition), but no one medication appears to be better than the others in improving these skills during the first two crucial months of treatment, according to the latest results from the NIMH-funded Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE).
New Details in Schizophrenia Treatment Trial Emerge
March 1, 2007 • Press Release
Two new studies from the Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) provide more insights into comparing treatment options, and to what extent antipsychotic medications help people with schizophrenia learn social, interpersonal and community living skills.
Common Gene Version Optimizes Thinking — but With a Possible Downside
February 9, 2007 • Press Release
Most people inherit a version of a gene that optimizes their brain’s thinking circuitry, yet also appears to increase risk for schizophrenia, a severe mental illness marked by impaired thinking, scientists at the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH) have discovered.
Gene Variant Linked to Schizophrenia
January 23, 2007 • Science Update
A gene implicated in schizophrenia in adults has now also been linked to schizophrenia in children for the first time, strengthening evidence that the gene plays a role in the disease.
Older Medication May Be More Cost-Effective for Some Patients with Schizophrenia
December 1, 2006 • Press Release
A new study analyzing the economic implications of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) concludes that the older (first generation) antipsychotic medication perphenazine was less expensive and no less effective than the newer (second generation) medications used in the trial during initial treatment, suggesting that older antipsychotics still have a role in treating schizophrenia.
New Schizophrenia Trial: Does Method of Administering Medication Make a Difference?
September 5, 2006 • Science Update
A new clinical trial is testing whether an injection of a long-lasting antipsychotic medication every two weeks results in better adherence to treatment and better outcomes among people with schizophrenia than do oral medications taken daily.
New Factors Identified for Predicting Violence in Schizophrenia
July 18, 2006 • Science Update
A study of adults with schizophrenia showed that symptoms of losing contact with reality, such as delusions and hallucinations, increased the odds of serious violence nearly threefold.
Studies ID Molecular Accomplices of Suspect Schizophrenia Genes
May 2, 2006 • Science Update
NIMH-funded researchers have discovered how certain genes work at the molecular level to increase the risk of schizophrenia.
Studies Offer New Information About Treatment Choices for Schizophrenia — Phase 2 Results
April 1, 2006 • Science Update
A national clinical trial comparing clozapine with other new-generation antipsychotic medications for the treatment of chronic schizophrenia has shown that people who switched to clozapine from their first medication because it failed to manage symptoms adequately were twice as likely to continue treatment as patients who switched to other antipsychotic medications.
1 | 2 | 3 | 4 | 5 | Next >